Daewon Pharmaceutical Co., Ltd. (003220.KS)

KRW 14020.0

(-1.2%)

Market Cap (In KRW)

300.49 Billion

Revenue (In KRW)

526.95 Billion

Net Income (In KRW)

23.91 Billion

Avg. Volume

1.43 Million

Currency
KRW
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
13350.0-20700.0
PE
-
EPS
-
Beta Value
0.42
ISIN
KR7003220001
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Seung-Ryel Baek
Employee Count
-
Website
https://www.daewonpharm.com
Ipo Date
2005-09-29
Details
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, produces and sells medicine and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis uses. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 45 countries primarily in Asia, Central and South America, the Middle East, etc. The company was founded in 1958 and is headquartered in Seoul, South Korea.